Arrowhead climbs on licensing agreement with Novartis for upto $2 billion

Arrowhead Pharmaceuticals

02/09/2025 18:01

Updates

** Shares of Arrowhead Pharmaceuticals ARWR.O rise 11.8% to $24.63

** Co says it will receive up to $2 billion from Novartis NOVN.S for an exclusive worldwide license to its experimental therapy ARO-SNCA that targets neuromuscular conditions such as Parkinson's disease

** Arrowhead will receive $200 million and up to $2 billion in milestone payments and royalties on future sales of the therapy

** Including session's move, stock was up 29.3% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))